On Oregon’s “Failed Experiment”

In March 2024, Oregon lawmakers voted to recriminalize the simple possession of small amounts of opioids, heroin, fentanyl, and other drugs—overturning Measure 110, the landmark 2020 voter initiative that had decriminalized personal possession in favor of a health-centered response. The reversal was sold as a necessary correction. Headlines, politicians, police unions, and prohibitionist voices pointed to the surge in overdose deaths after February 2021 as proof that removing criminal penalties had unleashed chaos. Media outlets from The Atlantic to The Wall Street Journal framed the tale as a cautionary one. A February 2024 WSJ opinion piece titled “Oregon Democrats Still Have a Drug Problem” declared Measure 110 a “failed experiment” but bypassed any rigorous examination of when the overdose surge actually began or how it compared to neighboring states.

This narrative was politically potent and emotionally resonant, but it was also arguably oversimplified—and it persisted despite substantial, peer-reviewed evidence to the contrary. A rigorous new study published in Academia Global and Public Health (April 2026) challenges the dominant “failure” narrative with hard data. However, this is not the first time researchers have pushed back against the public perception of the law. 

In September 2023, JAMA Psychiatry published a study using synthetic control methods on National Vital Statistics System data. It found no evidence that Measure 110 in Oregon—or the parallel policy change in Washington—was associated with changes in fatal drug overdose rates in the first full year after implementation. A Time magazine cover story on the findings was straightforward: “Decriminalizing Drug Possession Doesn’t Lead to More Fatal Overdoses.” In that piece, researchers noted that overdoses were rising long before the Oregon measure took effect and continued to rise in line with pre-existing regional trends driven by fentanyl. They also voiced suspicion that critics were taking an opportunistic swipe at Measure 110. Instead of engaging with this causal analysis, the media and political drumbeat continued, culminating in recriminalization only a few months later.

The new 2026 study suggests yet again that decriminalization was not the dominant factor in these rising fatalities. The Academia Global and Public Health study uses CDC Wonder monthly mortality data (2015–2023) for Oregon and its neighbors—California, Washington, Nevada, and Idaho. Employing a likelihood-based changepoint analysis (confirmed by joinpoint regression), the authors identify the most probable moment when overdose trends shifted. For Oregon, it was December 2019—a full 14 months before decriminalization. At that point, deaths jumped 29% in level and shifted from a flat trend to a steep +3.0% monthly increase. Neighboring states saw nearly identical breaks: Washington and California in March 2020, Nevada in April 2020, and Idaho later in April 2021. No state showed a meaningful inflection at or after the February 2021 implementation date. 

A properly specified difference-in-differences (DiD) model, accounting for non-parallel pre-trends, strengthens this interpretation: post-2021, a ~27% level increase hit everywhere. Oregon’s pre-existing lower baseline and slightly slower pre-trend simply continued; the analysis suggests the policy produced no statistically detectable extra harm. The JAMA synthetic control findings from 2023 are reinforced and extended here with two additional years of data and different analytic approaches. Earlier conflicting studies were overshadowed by headlines and one outlier analysis claiming “extra” deaths—yet both the 2023 and 2026 papers, using transparent, replicable methods (with all data public on GitHub), reach very similar conclusions.

There are understandable reasons the media treated the post-2021 numbers as self-evident proof of failure. There was visible disorder in Portland, open drug use, and heartbreaking overdose statistics. Critics of the measure point out that fatal overdose rates are not the sole metric of a policy's impact; the spike in open-air drug markets, public intoxication, and the resulting urban decay severely fractured public safety and community trust. Yet, few outlets paused to ask the necessary epidemiological and structural questions: When exactly did the rise begin? Did it happen elsewhere? Crucially, because the data reveal that Oregon's inflection point occurred in December 2019, its shift predates the pandemic. While neighboring states saw their trends break slightly later, in March and April 2020, these staggered timelines point to a rolling regional arrival of illicit fentanyl and possible lockdown shock in those states, rather than localized statutory changes. Ultimately, this data-driven perspective was drowned out by a public discourse that struggled to separate a regional surge from a localized change in state statute.

This is not the first time deeply ingrained reflexes and media incentives have produced incomplete assessments of drug reform. The pattern repeats: reformers propose evidence-based shifts; visible social problems—often driven by supply-side changes like potent synthetics—emerge; critics declare the reform the cause; and lawmakers and pundits choose the simplest story available.

The human cost of this rush to recriminalize is deeply concerning. Both studies note that reverting to criminal penalties risks returning vulnerable people to the justice system, with all its collateral damage—incarceration, lost jobs, family separation—while potentially doing nothing to reverse overdose trends. Recriminalization may satisfy a public craving for visible action, but there is little evidence it will save lives. The overdose crisis is fundamentally a tragedy of unaddressed demand—rooted in untreated addiction, poverty, and structural isolation—that was made more lethal by an ultra-potent supply of fentanyl. Criminal penalties have never solved it.

Oregon’s Measure 110 was imperfectly implemented and underfunded in key areas—that is fair criticism. Oregon’s harm-reduction infrastructure (methadone access, naloxone, treatment beds) remains woefully inadequate regardless of legal status. But blaming the measure for a regional fentanyl surge that began before the law and unfolded similarly next door is more akin to scapegoating than sound analysis. Unfortunately, the belief that drug decriminalization failed in Oregon is now embedded in the American psyche. Efforts to introduce alternative perspectives will be difficult, but they are essential if we are to prevent more deaths and harm from illicit drug use.